Other Collaboration Sample Clauses

Other Collaboration. SES Americom agrees, at Customer's request, to collaborate on the design and deployment of Customer's next-generation Ka-band satellite system, with possible operational or financing services to be provided by SES Americom. Any agreements resulting from such collaboration are subject to mutual agreement of the parties, each acting in its sole discretion.
AutoNDA by SimpleDocs
Other Collaboration. During the term of the Program, and in ------------------- the event that Albany desires to enter into a collaboration or other arrangement with a Third Party in the area of Combinatorial Technology research that would not utilize Lilly Licensed Technology or Program Technology, Albany shall inform the Program Chairs. The Program Chairs may approve or disapprove such proposed collaboration or other arrangement. In the event the Program Chairs disapprove, Albany shall not enter into such collaboration or other arrangement. In the event that the Program Chairs are unable to agree, such question shall be referred to the Executive Director of Lilly's Research Technologies for resolution. If such a collaboration or other arrangement is approved, any such collaboration or other arrangement conducted at Albany facilities shall be conducted in facilities that are separate from those facilities used to conduct the Program.
Other Collaboration i) As desired by the Parties, USAID and Peace Corps may also collaborate on other sector, program, national or regional initiatives that focus on building the capacity of local communities to implement sustainable development projects. For each of these specific collaborations, the parties will develop the goals, objectives and desired results, and indicate how each initiative will respond to one or more of the Intermediate Results for the Program.
Other Collaboration. In addition to our continuing work with XXXX, the University has submitted a Statement of Intent as one of the co-lead sponsors to develop a University Technical College in Nottingham. The UTC will provide high quality technical and vocational education and training to 14-19 year-olds. Local, regional and national employers will contribute to the design, development and delivery of the curriculum. The University’s contribution will harness the significant expertise and specialist facilities of our Faculty of Engineering and Centre for Sustainable Energy Technologies. The University will also be working with Broxtowe Borough Council in developing the XX Xxxxxxxx Heritage Centre, Durban House, and safeguarding its future. Durban House attracts visitors from all over the world, but the focus of current proposals is on supporting the University’s outreach activities with local schools in an area of social deprivation. Other joint opportunities include summer schools, creative writing links, short courses, lectures, events and exhibitions using material from the University archive. Durban House may develop into one of the Nottingham Potential centres.
Other Collaboration. This agreement does not exclude a collaboration of either of the contractual partners with third parties outside of the contractual subject matter or relating to the subject matter of this agreement.
Other Collaboration. For mutual benefits, the two parties might from time to time explore collaboration in other areas, including conducting joint research on issues of mutual interests. This MOU is a voluntary statement of the intention of cooperation between the two parties, is not intended to create any legally binding obligations, and neither party has the authority to act on behalf of or otherwise bind the other party. This MOU will be in force for a period of three years from the signing date and can be extended depending on the mutual interests of both parties. This MOU may be varied at any time by mutual agreement of both parties in writing. It can also be discontinued by either of the parties with a minimum of 30 days’ notice in writing to the other party. Any collaborative projects that are entered into under the terms of this MOU shall be negotiated and agreed by both parties and will be described in detail in working plans that will be annexed to this MOU or, if considered necessary, a formal legally binding contract. Each party will cover its own costs in implementing the terms of this MOU. For particular areas of cooperation, funding might be sought from other sources. Where specific projects are entered into that arise out of collaboration governed by this MOU, any financial arrangements between the two parties will be made and agreed on a case by case basis and formalized and documented separately from this MoU. The President of ANQAHE (at the time of signing Xx Xxxxx Xxxxxxx) and the Chief Executive of UK NARIC (at the time of signing Dr. Cloud Bai-Yun) will have responsibility for managing the implementation of the terms of this MOU. This responsibility may be delegated to relevant members of the agencies' staff in relation to particular areas of cooperation.
Other Collaboration. On the basis of equity collaboration as mentioned above, the Parties will engage in comprehensive communication and collaboration in the development of photovoltaic power station and other related areas of photovoltaic industry such as management, technology, research and development, etc. The Framework Agreement is an indication of the Parties’ intention to collaborate and the purpose, principle and content of collaboration as set out under the Framework Agreement do not impose any legal or binding obligations on either Party. The Parties will separately negotiate and enter into detailed and legally-binding definitive agreements upon:
AutoNDA by SimpleDocs
Other Collaboration. (a) Except as described in Paragraph 6(b), Shionogi shall have no obligation to provide assistance to InterMune in the Pirfenidone regulatory approval process within any of InterMune’s Respective Territories.

Related to Other Collaboration

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Conduct of Research Program Each Party:

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Research Program Term The Research Program shall be conducted during the period of five years commencing as of the Agreement Date ("Research Program Term"). Upon not later than seventy-five (75) days' prior written notice JT may, in its sole judgment, terminate the Research Program at the end of the third (3/rd/) year and fourth (4/th/) year of the Research Program. The RMC may terminate the Research Program any time during the Research Program Term if it unanimously determines the Research Program is no longer scientifically useful or that all potential Products would not be commercially viable. In case of such an early termination by JT or the RMC, JT shall be exempt from any payment(s) under Section 10(a) that would have become due and payable after the effective date of such early termination. Following any termination of the Research Program (i) that occurs simultaneously with the termination of this Agreement in accordance with Section 13 (i.e., no compound or Lead Compound has been designated previously a Collaboration Lead Compound in accordance with Section 3(b) and no Independent Lead Compound is being developed in accordance with Section 3(m)) or (ii) that is followed at some future date by the termination by JT of Development or co-promotion of any Collaboration Lead Compound and/or Product pursuant to Sections 3(l) or 5(c), respectively, or development of an Independent Lead Compound in accordance with Section 3(m) (A) any licenses granted by Tularik to JT will terminate, (B) JT will grant to Tularik an exclusive, sublicensable, worldwide license, to make, use and sell compounds, Collaboration Lead Compounds or Products under JT's interest in Program Patents and Program Know-How and (C) under the terms and conditions to be separately agreed, JT will also grant to Tularik a nonexclusive, sublicensable, worldwide license under any JT Patent Rights and Know-How to the extent necessary to practice the license granted under the Program Patents and Program Know-How in (B) (including, with respect to compounds, a limited number of JT's library compounds approved by JT); provided, however, that in the event the Research Program terminates but the Agreement has not terminated with respect to designated Collaboration Lead Compounds, Independent Lead Compounds and/or Products as provided in Section 2(g)(ii), Sections 2(g)(A), (B) and (C) shall apply only to those compounds, Collaboration Lead Compounds, Independent Lead Compounds and Products for which Development or co-promotion shall have been terminated and/or to those compounds or Lead Compounds that have not been designated previously a Collaboration Lead Compound in accordance with Section 3(b) or an Independent Lead Compound in accordance with Section 3(m); provided further that in the event that JT elects to pursue a Discontinued Compound or a Non-Proposed Compound on or before the first anniversary of the expiration or termination of the Research Program Term pursuant to Section 3(b)(iii) or 3(b)(iv), respectively, Sections 2(g)(A), (B) and (C) shall not apply to such Discontinued Compound or Non-Proposed Compound until such time as JT shall have terminated the Development or co-promotion of such Discontinued Compound or Non- Proposed Compound. Tularik will then be free to pursue clinical development and registration of such compounds, Lead Compounds and/or Products without obligation to JT except as provided in Section 4(f) or Section 5(c), as appropriate.

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Joint Patent Rights With respect to any potentially patentable Joint Invention, the Parties shall confer and agree upon which Party, if any, shall prepare, file, Prosecute (including any interferences, reissue proceedings, and other administrational proceedings) and Maintain patent applications covering such Joint Invention (any such patent application and any patents issuing therefrom a “Joint Patent Right”), at the responsible Party’s expense. It is the intention of the Parties that, unless otherwise agreed in writing, ATI would prepare, file, Prosecute and Maintain any Joint Patent Rights. The Party that Prosecutes a patent application in the Joint Patent Rights (the “Prosecuting Party”) shall provide the other Party reasonable opportunity to review and comment on such Prosecution efforts regarding the applicable Joint Patent Rights in the particular jurisdictions, and such other Party shall provide the Prosecuting Party reasonable assistance in such efforts. The Prosecuting Party shall provide the other Party with a copy of all material communications from any patent authority in the applicable jurisdictions regarding the Joint Patent Rights being Prosecuted by such Party, and shall provide drafts of any material filings or responses to be made to such patent authorities a reasonable amount of time in advance of submitting such filings or responses. In particular, each Party agrees to provide the other Party with all information necessary to enable the other Party to comply with the duty of candor/duty of disclosure requirements of any patent authority. Should ATI determine that it will no longer support the continued Prosecution or Maintenance of a particular Joint Patent Right in a country or jurisdiction, ATI shall provide Rigel with written notice of such determination at least thirty (30) Business Days prior to any deadline for taking action to avoid abandonment of such Joint Patent Right. Rigel shall have the right, but not ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 obligation, to file, Prosecute and Maintain such Joint Patent Rights in the applicable jurisdiction at Rigel’s expense.

  • Commercialization Diligence Novartis shall dedicate commercially reasonable efforts, during each [**] month period, necessary to commercialize a Licensed Product for a Profile, after receipt of Regulatory Approval therefor, in any of the U.S., Japan or the EU Major Market Countries. If Novartis commercializes a Licensed Product for a Profile, after receipt of Regulatory Approval therefor, in any of the U.S., Japan or the EU Major Market Countries, Novartis will be deemed to satisfy all diligence obligations with respect to such Profile.

Time is Money Join Law Insider Premium to draft better contracts faster.